BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bionomics Limited (BMICY.PK) Start-Up Placement with Australian Ventures


9/3/2009 1:30:26 PM

Thursday 3 September 2009 - Adelaide, Australia: Bionomics Limited (ASX:BNO) today announced that it has entered into a Subscription Agreement with Start-up Australia Ventures Pty Ltd as trustee of the Start-up Australia Trust (Start-up) for a $7 million placement of ordinary shares to Start-up.

Start-up has access to funding from the Australian Government’s Innovation Investment Follow-on Fund for the purpose of taking up the placement.

Dr George Jessup, Managing Director of Start-up, commented “I am delighted with the continued progress of Bionomics. The company has two exciting new drugs in clinical trials and a high value partnership with a major European pharmaceutical company. They have achieved this with a very efficient use of shareholder funds. This new funding will allow the company to achieve critical value adding milestones for investors and is also important for patients who are in need of these drugs."

The placement to Start-up is conditional on:

(a) Bionomics’ shareholders resolving at a general meeting to approve, for the purposes of item 7 of section 611 of the Corporations Act, the acquisition of the placement shares by Start-up; and

(b) Bionomics raising a further $5 million through private placements to institutional or sophisticated investors.

About Bionomics Limited

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES